Atorvastatin plus pravastatin for the treatment of heterozygous familial hypercholesterolaemia - A pilot study

Current Medical Research and Opinion

Volumn 17, Issue 4, 2001, Pages 267-272

  Athyros, Vasilios G ^a   Papageorgiou, Athanasios A ^a   Demitriadis, Dimokritos S ^a   Kontopoulos, Athanasios G ^a  

^a NONE   (Greece)

Author keywords

Atorvastatin; Combination therapy; Familial hypercholesterolaemia; Pravastatin

Indexed keywords

ATORVASTATIN; COLESTYRAMINE; CYTOCHROME P450 2C9; CYTOCHROME P450 3A4; FIBRINOGEN; HIGH DENSITY LIPOPROTEIN CHOLESTEROL; LIPOPROTEIN A; LOW DENSITY LIPOPROTEIN CHOLESTEROL; PRAVASTATIN; TRIACYLGLYCEROL;

ARTICLE; CHOLESTEROL BLOOD LEVEL; CLINICAL ARTICLE; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; CORONARY ARTERY DISEASE; DRUG EFFICACY; DRUG METABOLISM; DRUG POTENTIATION; FAMILIAL HYPERCHOLESTEROLEMIA; FEMALE; HETEROZYGOSITY; HUMAN; LIPOPROTEIN BLOOD LEVEL; LIVER TOXICITY; MALE; MYOPATHY;

ANALYSIS OF VARIANCE; ANTICHOLESTEREMIC AGENTS; DRUG THERAPY, COMBINATION; FEMALE; HEPTANOIC ACIDS; HUMANS; HYPERLIPOPROTEINEMIA TYPE II; MALE; MIDDLE AGED; PILOT PROJECTS; PRAVASTATIN; PROSPECTIVE STUDIES; PYRROLES; TREATMENT OUTCOME;

EID: 0035713438     PISSN: 03007995     EISSN: None     Source Type: Journal    
DOI: 10.1185/030079901753403162     Document Type: Article

References (35)

1. Baycol withdrawn from market
2. Bayer decides to withdraw cholesterol lowering drug
3. Comparative tolerability of the HMG-CoA reductase inhibitors
4. Executive Summary of The Third Report of the National Cholesterol Education Program (NCEP) Expert Panel on Detection, Evaluation, and Treatment of High Blood Cholesterol in Adults (Adult Treatment Panel III)
5. Equally potent inhibitors of cholesterol synthesis in human hepatocytes have distinguishable effects on different cytochrome P450 enzymes
6. Does differing metabolism by cytochrome p450 have clinical importance?
7. Treatment of heterozygous familial hypercholesterolemia with lipid-lowering drugs
8. Comparative dose efficacy study of atorvastatin versus simvastatin, pravastatin, lovastatin, and fluvastatin in patients with hypercholesterolemia (the CURVES study)
9. Efficacy of atorvastatin in achieving National Cholesterol Education Program low-density lipoprotein targets in women with severe dyslipidemia and cardiovascular disease or risk factors for cardiovascular disease: The Women's Atorvastatin Trial on Cholesterol (WATCH)
10. The efficacy of atorvastatin in treating patients with hypercholesterolaemia to target LDL-cholesterol goals: The LIPI-GOAL trial
11. Treatment of heterozygous familial hypercholesterolemia: Atorvastatin vs. simvastatin
12. Effects of atorvastatin versus fenofibrate on lipoprotein profiles, low-density lipoprotein subfraction distribution, and hemorheologic parameters in type 2 diabetes mellitus with mixed hyperlipoproteinemia
13. Effect of niacin and atorvastatin on lipoprotein subclasses in patients with atherogenic dyslipidemia
14. HDL-cholesterol and the treatment of coronary heart disease: Contrasting effects of atorvastatin and simvastatin
15. A comparison of simvastatin and atorvastatin up to maximal recommended doses in a large multicenter randomized clinical trial
16. HMG-CoA reductase inhibitors: Assessing differences in drug interactions and safety profiles
17. The treatment of coronary heart disease: Statins beyond cholesterol lowering
18. Similar effects of atorvastatin, simvastatin and pravastatin on thrombogenic and inflammatory parameters in patients with hypercholesterolemia
19. Effect of hydroxymethyl glutaryl coenzyme A reductase inhibitor therapy on high sensitive C-reactive protein levels
20. Benefits of lipid lowering on vascular reactivity in patients with coronary artery disease and average cholesterol levels: A mechanism for reducing clinical events?
21. Improvement of nitric oxide dependent vasodilatation by HMG-CoA reductase inhibitors through attenuation of endothelial superoxide anion formation
22. Atorvastatin upregulates type III nitric oxide synthase in thrombocytes, decreases platelet activation, and protects from cerebral ischemia in normocholesterolemic mice
23. Effect of atorvastatin and fluvastatin on the expression of plasminogen activator inhibitor type-1 in cultured human endothelial cells
24. 2+ release and vascular reactivity
25. Fibromuscular cap composition is important for the stability of established atherosclerotic plaques in mature WHHL rabbits treated with statins
26. Statins alter smooth muscle cell accumulation and collagen content in established atheroma of Watanabe heritable hyperlipidemic rabbits
27. The treatment of coronary heart disease: An overview of the risk factors for cardiovascular disease
28. Fibrinogen and cardiovascular risk
29. The effect of atorvastatin on serum lipids, lipoprotein(a) and plasma fibrinogen levels in primary dyslipidaemia - A pilot study involving serial sampling
30. Comparative study of HMG-CoA reductase inhibitors on fibrinogen
31. Effect of atorvastatin on serum uric acid levels
32. Development of tachyphylaxis among patients taking HMG CoA reductase inhibitors
33. Additive effects of another kind of HMG-CoA reductase inhibitor with different pharmacokinetics in the treatment of heterozygous familial hypercholesterolemia
34. Aggressive therapy and combination therapy in severe hyperlipidemia